Findings

What do systematic reviews say?

27 questions · 27 findings · 4 reviews · Schizophrenia

Sort:Best matchNewest Highest certainty Download CSV

No studies found 7 · 25.9%GRADE not reported 6 · 22.2%Very low 14 · 51.9%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Cognitive training vs active control

Satisfaction with treatment: 1. Leaving the study early ‐ long term · people in the prodromal stage of psychosis

It is very uncertain whether group C other: cognitive training changes satisfaction with treatment: leaving the study early Endpoint data… compared with active control (tablet games) (very low certainty).

1 finding from 1 review

Interventions for prodromal stage of psychosis 2019 · Cochrane Headline outcomes only
RR 0.78 [0.48, 1.29]
1 study · 83 participants
Very low

Benzodiazepines vs phenobarbital (as active placebo)

Adverse effect: extrapyramidal symptoms ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia

The review found no eligible studies for this question.

1 finding from 1 review

Benzodiazepines for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Benzodiazepines vs phenobarbital (as active placebo)

Acceptability · patients with antipsychotic‐induced tardive dyskinesia

1 finding from 1 review

Benzodiazepines for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 21 participants
Very low

Benzodiazepines vs phenobarbital (as active placebo)

Social confidence, social inclusion, social networks, or personalised quality of life ‐ not measured · patients with antipsychotic‐induced tardive dyskinesia

The review found no eligible studies for this question.

1 finding from 1 review

Benzodiazepines for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Benzodiazepines vs phenobarbital (as active placebo)

Tardive dyskinesia: No clinically important improvement · patients with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether benzodiazepines changes tardive dyskinesia: no clinically important improvement compared with phenobarbital (as active placebo) (very low certainty).

1 finding from 1 review

Benzodiazepines for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
RR 0.44 [0.2, 0.96]
1 study · 21 participants
Very low

Benzodiazepines vs phenobarbital (as active placebo)

Tardive dyskinesia: deterioration in symptoms ‐ not measured · patients with antipsychotic‐induced tardive dyskinesia

The review found no eligible studies for this question.

1 finding from 1 review

Benzodiazepines for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Benzodiazepines vs phenobarbital (as active placebo)

Adverse events: any · patients with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether benzodiazepines changes adverse events: any compared with phenobarbital (as active placebo) (very low certainty).

1 finding from 1 review

Benzodiazepines for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
RR 1.53 [0.97, 2.41]
1 study · 21 participants
Very low